MCMing Chen

Ming Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ming Chen has a total of 98 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Lai

    State Key Laboratory of Brain Function and Disorders, Institutes of Brain Science, MOE Frontier Center for Brain Science, Department of Neurology of Zhongshan Hospital, Fudan University, Shanghai, China

    9 shared publications
  • Ping Zheng

    State Key Laboratory of Brain Function and Disorders, Institutes of Brain Science, MOE Frontier Center for Brain Science, Department of Neurology of Zhongshan Hospital, Fudan University, Shanghai, China

    9 shared publications
  • Huan Sheng

    State Key Laboratory of Brain Function and Disorders, Institutes of Brain Science, MOE Frontier Center for Brain Science, Department of Neurology of Zhongshan Hospital, Fudan University, Shanghai, China

    6 shared publications
  • Da Shao

    State Key Laboratory of Brain Function and Disorders, Institutes of Brain Science, MOE Frontier Center for Brain Science, Department of Neurology of Zhongshan Hospital, Fudan University, Shanghai, China

    5 shared publications
  • Dongyang Cui

    State Key Laboratory of Medical Neurobiology Institutes of Brain Science MOE Frontier Center for Brain Science Department of Neurology of Zhongshan Hospital Fudan University Shanghai 200032 China

    5 shared publications
  • Li Yang

    State Key Laboratory of Brain Function and Disorders, Institutes of Brain Science, MOE Frontier Center for Brain Science, Department of Neurology of Zhongshan Hospital, Fudan University, Shanghai, China

    5 shared publications

Latest Publications

  • Two distinct projection pathways converge onto the same BLA neurons to contribute to fear memory retrieval

    by Hao Yang, Ting Xia, Siying Kuang, Yali Fu, Zixuan Cao, Yaxian Wen, Yu Yuan, Chenshan Chu, Xinli Guo, Li Yang, et al.

    Studying the neural circuits that mediate context-induced fear memory retrieval is of importance to develop new therapeutic approaches to prevent post-traumatic stress disorder relapse. The basolateral amygdala (BLA) is crucial for context-induced retrieval of fear memory. Previous studies indicate that projection neurons from the ventral hippocampus CA1 (vCA1) to the BLA (vCA1-BLA neurons) mediate context-induced retrieval of fear memory. However, it remains unclear whether other projection neurons to the BLA are involved in context-induced retrieval of fear memory and how they interact with vCA1-BLA neurons. Our findings indicate that the postrhinal cortex (POR) to the BLA (POR-BLA) neurons are also involved in context-induced retrieval of fear memory. These neurons innervate the same BLA neurons as vCA1-BLA neurons and participate in fear memory retrieval. These results suggest that two different projection neurons of POR-BLA and vCA1-BLA innervate on the same BLA neurons and POR-BLA neurons and vCA1-BLA neuron contribute to fear memory retrieval. These findings provide new insights into the neural mechanisms underlying fear memory retrieval.

  • BLA astrocytes are associated with withdrawal somatic signs during high-dose naloxone-precipitated morphine withdrawal revealed by 3D-AI behavioral analysis

    by Zhangyin Cai, Kaiman Chang, Rong Fan, Yuanqi Chen, Ke Xu, Qianru Shen, Tzu Yu Sun, Yaxian Wen, Yu Yuan, Siying Kuang, et al.

  • Open Access

    Peroxisome Proliferator‑Activated Receptor Gamma Coactivator‑1α Deficiency in Hippocampal Astrocytes Underlies Enhanced Fear Memory Retrieval in Male Posttraumatic Stress Disorder Model Mice

    by Juan Wang, Xiaoyu Chen, Daokang Chen, Shaojie Yang, Jingji Wang, Ming Chen, Guoqi Zhu

    Peroxisome proliferator‑activated receptor gamma coactivator‑1α (PGC‑1α), a key metabolic regulator, is implicated in astrocyte function, but its specific role during fear memory retrieval and in posttraumatic stress disorder (PTSD) pathogenesis remains unclear. Here, using the single‐prolonged stress mice model, we demonstrated a significant downregulation of PGC‑1α specifically within hippocampal astrocytes, concomitant with reduced astrocyte density, attenuated intracellular Ca 2 + signaling, and impaired activity‑dependent ATP release. Targeted knockdown of hippocampal astrocytic PGC‑1α in vivo was sufficient to potentiate fear memory retrieval. This behavioral enhancement was associated with a loss of complex astrocyte morphology, further suppression of ATP release, aberrant hippocampal neuronal activity, and a marked decrease in connexin 43 (CX43) expression. Notably, pharmacological inhibition of CX43‑based gap junctions mimicked this pro‑fear phenotype in control animals. Conversely, interventions either via chemogenetic activation of astrocytes or administration of PGC‑1α agonists effectively normalized fear memory responses and rescued CX43 levels in PTSD mice. Crucially, the therapeutic benefit of chemogenetic astrocyte activation was abolished when PGC‑1α was concomitantly knocked down. Collectively, our results demonstrate that PGC‐1α deficiency in hippocampal astrocytes underlies enhanced fear memory retrieval in PTSD model mice, highlighting the potential of astrocyte‑targeted strategies for preventing and treating PTSD.


  • Open Access

    Corticosterone Contributes to Context‐Triggered Retrieval of Morphine Withdrawal Memories by Acting on Basolateral Amygdala Neurons Projecting to Nucleus Accumbens Core

    by Zixuan Cao, Yaxian Wen, Yuanqi Chen, Yali Fu, Hao Yang, Chenshan Chu, Xinli Guo, Yu Yuan, Chao Lei, Huan Sheng, et al.

    Context‐triggered retrieval of drug withdrawal memories (CTR‐DWM) is a major cause of drug relapse. Most studies of the context‐triggered retrieval of morphine withdrawal memories (CTR‐MWM) have mainly focused on the functional interactions within the central structures of the brain. It remains unknown how an increase in corticosterone, which is an important response under drug withdrawal state, participates in CTR‐MWM. The present results show that corticosterone contributes to CTR‐MWM; within the basolateral amygdala (BLA), it is the mineralocorticoid receptor (MR), rather than the glucocorticoid receptor (GR), activated by corticosterone that mediates CTR‐MWM; MR of BLA neurons projecting to the nucleus accumbens core (BLA →NAcC ) mediates CTR‐MWM; MR increases presynaptic glutamate release and participates in dopamine D1 receptor ‐induced increase in presynaptic glutamate release and postsynaptic AMPA (α‐Amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic Acid) currents; MR increases intrinsic excitability of BLA →NAcC neurons during CTR‐MWM. These results suggest that corticosterone contributes to CTR‐MWM by activating BLA →NAcC neurons through MR pathways, uncovering a link between a systemic hormonal response and a specific CTR‐MWM process.


  • Open Access

    Instant noninvasive near-infrared deep brain stimulation using optoelectronic nanoparticles without genetic modification

    by Shuang Jin, Jiazhi Li, Luyue Jiang, Yifei Ye, Chenguang Ma, Yingkang Yang, Haoyang Su, Lusha Gao, Min Ni, Yiping Zhao, et al.

    Noninvasive transcranial neuromodulation of deep brain regions is a longstanding goal in neuroscience. While optogenetics enables remote neural control, it is constrained by shallow tissue penetration of visible light and delayed onset due to required opsin expression. Here, we introduce a neuromodulation technique using hybrid upconversion and photovoltaic (HUP) nanoparticles, which eliminates the need for genetic modification and affords near-infrared (NIR) activation of neurons in wild-type mice. This method converts deeply penetrating NIR light into localized electrical stimuli, enabling immediate and precise modulation in deep brain. In vitro patch-clamp experiments confirm neuronal activation upon HUP application. In vivo, we achieve remote NIR neuromodulation in the medial septum and ventral tegmental area 7 days postinjection, effectively modulating neuronal activity, suppressing seizures, and triggering dopamine release. This minimally invasive approach offers a versatile tool kit for investigating neural processes in mammals, with potential applications across diverse brain regions through customizable nanoparticle engineering.


  • Open Access

    mPFC DCC coupling with CaMKII+ neuronal excitation participates in behavioral despair in male mice

    by Ping Cheng, Keke Ding, Daokang Chen, Chen Yang, Juan Wang, Shaojie Yang, Ming Chen, Guoqi Zhu

    A longed lack of control over harmful stimuli can lead to learned helplessness (LH), a significant factor in depression. However, the cellular and molecular mechanisms underlying LH, and eventually behavioral despair, remain largely unknown. The deleted in colorectal cancer (dcc) gene is associated with the risk of depression. However, the therapeutic potential and regulation mechanism of DCC in behavioral despair are still uncertain. In this study, we showed that depressive stimulators, including LH, lipopolysaccharide, and unpredictable chronic mild stress, triggered an elevation in DCC expression in the medial prefrontal cortex (mPFC). Additionally, elevated DCC expression in the mPFC was crucial in inducing behavioral despair, as evidenced by the induction of behavioral despair in normal mice and exacerbation of behavioral despair in LH mice upon DCC overexpression. By contrast, neutralizing DCC activity ameliorated LH-induced behavioral despair. Importantly, we elucidated that pathological DCC expression was attributable to the excessive excitation of CaMKII+ neurons in a manner dependent on the calpain-mediated degradation of SCOP and aberrant phosphorylation of the ERK signaling pathway. In addition, the increase in DCC expression led to a decreased excitability threshold in CaMKII+ neurons in the mPFC, which was supported by the observation that the ligand netrin 1 increased the frequency of action potential firing and of spontaneous excitatory postsynaptic currents in CaMKII+ neurons. In conclusion, our data indicate that LH triggers the excessive excitation of CaMKII+ neurons and activation of calpain-SCOP/ERK signaling to promote DCC expression, and DCC represents a crucial target for the treatment of LH-induced behavioral despair in male mice.


  • Open Access

    Projection neurons from medial entorhinal cortex to basolateral amygdala are critical for the retrieval of morphine withdrawal memory

    by Yali Fu, Zixuan Cao, Ting Ye, Hao Yang, Chenshan Chu, Chao Lei, Yaxian Wen, Zhangyin Cai, Yu Yuan, Xinli Guo, et al.


  • Open Access

    Intranasal Administration of Apelin-13 Ameliorates Cognitive Deficit in Streptozotocin-Induced Alzheimer’s Disease Model via Enhancement of Nrf2-HO1 Pathways

    by Hai Lu, Ming Chen, Cuiqing Zhu

    Background: The discovery of novel diagnostic methods and therapies for Alzheimer’s disease (AD) faces significant challenges. Previous research has shed light on the neuroprotective properties of Apelin-13 in neurodegenerative disorders. However, elucidating the mechanism underlying its efficacy in combating AD-related nerve injury is imperative. In this study, we aimed to investigate Apelin-13’s mechanism of action in an in vivo model of AD induced by streptozocin (STZ). Methods: We utilized an STZ-induced nerve injury model of AD in mice to investigate the effects of Apelin-13 administration. Apelin-13 was administered intranasally, and cognitive impairment was assessed using standardized behavioral tests, primarily, behavioral assessment, histological analysis, and biochemical assays, in order to evaluate synaptic plasticity and oxidative stress signaling pathways. Results: Our findings indicate that intranasal administration of Apelin-13 ameliorated cognitive impairment in the STZ-induced AD model. Furthermore, we observed that this effect was potentially mediated by the enhancement of synaptic plasticity and the attenuation of oxidative stress signaling pathways. Conclusions: The results of this study suggest that intranasal administration of Apelin-13 holds promise as a therapeutic strategy for preventing neurodegenerative diseases such as AD. By improving synaptic plasticity and mitigating oxidative stress, Apelin-13 may offer a novel approach to neuroprotection in AD and related conditions.


  • Open Access

    Intranasal Administration of Apelin-13 Ameliorates Cognitive Deficit in STZ-Induced Alzheimer’s Disease Model via Enhancement of Nrf2-HO1 Pathways

    by Hai Lu, Ming Chen, Cuiqing Zhu

    (1) Background: Alzheimer’s disease (AD) presents a significant challenge in terms of discovering novel diagnostic methods and therapies. Previous research has shed light on the neuroprotective properties of Apelin-13 in neurodegenerative disorders. However, elucidating the mechanism underlying its efficacy in combating AD-related nerve injury is imperative. In this study, we aimed to investigate the mechanism of action of Apelin-13 in an in vivo model of AD induced by streptozocin (STZ); (2) Methods: We utilized an STZ-induced nerve injury model of AD in mice to investigate the effects of Apelin-13 administration. The Apelin-13 was administered intranasally, and cognitive impairment was assessed using standardized behavioral tests. The main methods included behavioral assessment, histological analysis, and biochemical assays to evaluate synaptic plasticity and oxidative stress signaling pathways; (3) Results: Our findings indicate that intranasal administration of Apelin-13 ameliorated cognitive impairment in the STZ-induced AD model. Furthermore, we observed that this effect was potentially mediated through the enhancement of synaptic plasticity and attenuation of oxidative stress signaling pathways; (4) Conclusions: The results of this study suggest that intranasal administration of Apelin-13 holds promise as a therapeutic strategy for preventing neurodegenerative diseases such as AD. By improving synaptic plasticity and mitigating oxidative stress, Apelin-13 may offer a novel approach to neuroprotection in AD and related conditions.